iTeos Therapeutics, Inc.
ITOS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $434 | $258 | $311 | $440 |
| - Cash | $208 | $157 | $142 | $124 |
| + Debt | $5 | $5 | $5 | $6 |
| Enterprise Value | $232 | $107 | $174 | $322 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$34 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$66 | -$34 | -$48 | -$48 |
| % Margin | – | – | – | – |
| Net Income | -$79 | -$35 | -$44 | -$45 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.81 | -0.8 | -1.08 | -1.05 |
| % Growth | -126.3% | 25.9% | -2.9% | – |
| Operating Cash Flow | -$42 | -$34 | $5 | -$37 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$43 | -$34 | $5 | -$37 |